Business
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
Patients Who Achieved SDI at Any Timepoint Maintained it at All Future Timepoints; Higher Proportion of Patients Showing SDI with Increasing Dose Patients
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":"\nPatients Who Achieved SDI at Any Timepoint Maintained it at All Future Timepoints; Higher Proportion of Patients Showing SDI with Increasing Dose\n\n\nPatients Achieving SDI Also Demonstrated Trend Toward Improvement in Fatigue and Physical Function at 12 Months \n\n\nFirst Available Data from Open Label Expansion Show Patients with SDI at 12 Months, Maintained SDI at Later Time Points \n\n\nConference Call and Webcast Today, September 11, 2020 at 8:30 a.m. ET\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nAtara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of data from the first part of the ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). ATA188 is an off-the-shelf, allogeneic EBV-specific T-cell immunotherapy. These data demonstrate that ATA188 was well-tolerated across all four dose cohorts; patients who achieved sustained disability improvements at any timepoint maintained it at all future timepoints and a higher proportion of patients showed sustained disability improvements (SDI) with increasing dose. The results are featured in an e-poster at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, held September 11-13, 2020.\n\n\n“It is very encouraging to see that patients receiving ATA188 who achieved sustained disability improvement at any time point maintained it at all future time points and tended to also show improvements in fatigue and physical function at 12 months,” said Jakob Dupont, Global Head, Research and Development. “These results together with a favorable safety profile highlight the potential of ATA188 for patients with progressive MS and reinforce our excitement around advancing the randomized placebo-controlled portion of the study which is currently enrolling.”\n\n\nThis Phase 1a multicenter, open-label study of ATA188 in patients with progressive forms of MS was designed to establish safety and tolerability, to select the recommended dose for the randomized placebo-controlled Phase 1b study, which is currently actively recruiting, and to assess potential efficacy. Patients were treated across four dose-escalating coho...